Hypertension Therapeutics Update: A Brief Clinical Summary on Azilsartan, Cilnidipine and Nebivolol
Article Sidebar
Main Article Content
Abstract
Uncontrolled hypertension is the major risk factor for cardiovascular disease. The economic burden of disease is enormous in developed as well as in developing countries. The epidemiological studies have explained many etiological factors associated with chronic untreated hypertension, which varies according to geography and ethnicity. In last five decades, many classes and types of antihypertensive drugs have been developed. This pharmacological review provides an update on new molecules belonging to three pharmacological classes of antihypertensives—angiotensin receptor blocker (azilsartan), calcium channel blocker (cilnidipine) and beta-blocker (nebivolol), and their clinical implications.
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
All open access articles published in the journal are distributed under the terms of the CC-BY-NC-SA 4.0 license (Creative Commons Attribution-Non-commercial 4.0 International License) which permits unrestricted use, distribution, and reproduction in any medium, for non-commercial purposes, provided the original work is properly cited. Under Creative Commons, authors retain copyright in their articles.
References
Ram CV. Angiotensin receptor blockers: current status and future prospects. Am J Med 2008;121(8):656-663.
Ram CV, Ramaswamy K, Qian C, et al. Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data. J Clin Hypertens (Greenwich) 2011;13(11):801-812.
Maggioni AP. Efficacy of angiotensin receptor blockers in cardiovascular disease. Cardiovasc Drugs Ther 2006;20(4): 295-308.
Zaiken K, Cheng JW. Azilsartan medoxomil: a new angiotensin receptor blocker. Clin Ther 2011;33(11):1577-1589.
Bakris GL, Sica D, Weber M, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich) 2011; 13(2):81-88.
White WB, Weber MA, Sica D, et al. Effects of angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stage 1 and 2 hypertension. Hypertension 2011;57(3):413-420.
Kurtz TW, Kajiya T. Differential pharmacology and benefit/ risk of azilsartan compared to other sartans. Vasc Health Risk Manag 2012;8:133-143.
Khan MA, Neckar J, Cummens B, Wahl GM, Imig JD. Azilsartan decreases renal and cardiovascular injury in the spontaneously hypertensive obese rat. Cardiovasc Drugs Ther 2014;28(4):313-322.
Ojima M, Hideki I, Masayuki T, et al. In vitro antagonistic properties of a new angiotensins in type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011;336(3):801-808.
Ram CV. Angiotensin receptor blockers: current status and future prospects. Am J Med 2008;121:656-663.
. 11. Ram CVS. Calcium antagonists in the treatment of hypertension. Am J Med Sci 1985;290(8):118-132.
Grassi G. Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Hypertens Res 2006;29(11):839-847.
Takahara A. Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovasc Ther 2009;27(2):124-139.
Konda T, Enomoto A, Aritomi S, Niinuma K, Koganei H, Ogawa T, et al. Different effects of L/N-type and L-type calcium channel blockers on the renin–angiotensin– aldosterone system in SHR/Izm. Am J Nephrol 2009;30(2): 155-161.
Konoshita T, Makino Y, Kimura T, Fujii M, Wakahara S, Arakawa K, et al. A new-generation N/L-type calcium channel blocker leads to less activation of the renin– angiotensin system compared with conventional L-type calcium channel blocker. J Hypertens 2010;28(10):2156-2160.
Takeda S, Ueshiba H, Hattori Y, Irie M. Cilnidipine, the N- and L-type calcium antagonist, reduced on 24-hour urinary catecholamines and C-peptide in hypertensive noninsulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1999;44(3):197-205.
Konda T, Enomoto A, Takahara A, Yamamoto H. Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats. Biol Pharm Bull 2006;29(5):933-937.
Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, IsshikiM, et al. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin–angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007;72(12):1543-1549.
Tanaka M. The L/N-type calcium channel blocker, cilnidipine, reduces heart rate and albuminuria in patients with type 2 diabetes. J Int Med Res 2010;38(2):602-610.
Konda T, Enomoto A, Matsushita J, Takahara A, Moriyama T. The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. Nephron Physiol 2005;101(1):1-13.
Konno Y, Kimura K. Vasodilatory effect of cilnidipine, an L-type and N-type calcium channel blocker, on rat kidney glomerular arterioles. Int Heart J 2008;49(6):723-732.
Katayama K, Nomura S, Ishikawa H, Murata T, Koyabu S, Nakano T. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria. Kidney Int 2006;70(1):151-156.
Kuroedov A, Cosentino F, Luscher TF. Pharmacological mechanisms of clinically favourable properties of a selective beta1-adrenoceptor antagonist, nebivolol. Cardiovasc Drug Rev 2004;22(3):155-168.
Uhlir O, Dvorak I, Gregor P, et al. Nebivolol in the treatment of cardiac failure: a double-blind controlled clinical trial. J Card Fail 1997;3(4):271-276.
De Boer RA, Voors AA, Van Veldhuisen DJ. Nebivolol: third-generation beta-blockade. Expert Opin Pharmacother 2007;8(10):1539-1550.
Pauwels PJ, Gommeren W, Van Lommen G, et al. The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various b-adrenergic blockers. Mol Pharmacol 1988;34(6):843-851.
Maffei A, Lembo G. Nitric oxide mechanism of Nebivolol. Ther Adv Cardiovasc Dis 2009 Aug;3(4):317-327.
De Cree J, Van Rooy P, Geukens H, et al. The antihypertensive and cardiac hemodynamic effects of nebivolol. Angiology 1992;43(5):396-377.
Cheymol G, Woestenborghs R, Shoeck, et al. Pharmacokinetics of nebivolol: a review. Drug Invest 1991;3(1):25-30.
Broeders MA, Doevendans PA, Bekkers BC, et al. Nebivolol: a third generation beta blocker that augments vascular nitric oxide release: endothelial beta (2)-adrenergic receptor mediated nitric oxide production. Circulation 2000;102(6):677-684.
Bundkirchen A, Brixius K, Bolck B, Nguyen Q, Schwinger RH. Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol: a comparison of (3H) CGP 12.177 and (1251) iodocyanopindolol binding studies. Eur J Pharmacol 2003;460(1):19-26.
Fogari R, Zoppi A, Lazzari P, et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens 1997;11(11):753-757.
Poirier L, Cleroux J, Nadeau A, Lacourciere Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 2001;19(8):1429-1435.
Pessina AC. Metabolic effects and safety profile of nebivolol. J Cardiovasc Pharmacol 2001;38(3):S33-35.
Flather M, Shibata M, Coats A, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26(3):215-225.
McMurray J. Making sense of SENIORS. Eur Heart J 2005; 26(3):203-206.
Ram CVS. Beta-blockers in hypertension. Am J Cardiology 2010;106(12):1819-1825.
Ram CVS. Beta-blockers in hypertension. Truths and halftruths. J Clinical Hypertens 2008;10(7):516-519.
Nebivolol. The first highly selective b1-blocker with NO nitric oxide modulating properties: nebivolol monograph. Churchill Communications Europe, London; 1996.